AIDS最新文献

{"title":"Point-of-care urine tenofovir test predicts future HIV preexposure prophylaxis discontinuation among young users.","authors":"Tyler Martinson, Rikki Montoya, Carlos Moreira, Karen Kuncze, Kevin Sassaman, Megan J Heise, David V Glidden, K Rivet Amico, Emily A Arnold, Susan P Buchbinder, Leah Davis Ewart, Adam Carrico, Guohong Wang, Hideaki Okochi, Hyman M Scott, Monica Gandhi, Matthew A Spinelli","doi":"10.1097/QAD.0000000000003962","DOIUrl":"10.1097/QAD.0000000000003962","url":null,"abstract":"<p><strong>Background: </strong>Young men who have sex with men and transgender women (YMSM/TGW) have disproportionately high HIV incidence and lower preexposure prophylaxis (PrEP) adherence. Point-of-care (POC) urine tenofovir (TFV) rapid assay (UTRA) testing permits real-time monitoring for nonadherence within clinical settings. We performed UTRA testing among PrEP users to examine the relationship between low PrEP adherence and future PrEP discontinuation, and the accuracy of POC testing compared to gold-standard liquid chromatography tandem mass spectrometry (LC/MS/MS).</p><p><strong>Methods: </strong>YMSM/TGW participants ( n  = 100) were recruited during a daily PrEP visit. Logistic regression models analyzed the relationship between the primary predictor of urine POC assay results (cutoff 1,500 ng/ml) and the primary outcome of PrEP discontinuation, defined as no PrEP follow-up or prescription within 120 days.</p><p><strong>Results: </strong>Overall, 19% of participants had low urine TFV and 21% discontinued PrEP, while 11% of participants self-reported low PrEP adherence (<4 pills per week), which was only 43% sensitive/84% specific in predicting low TFV levels and was not associated with PrEP discontinuation. Low urine TFV level predicted PrEP discontinuation [adjusted odds ratio (AOR) 6.1; 95% confidence interval (CI): 1.4-11; P  = 0.005] and was 71% sensitive/90% specific for discontinuation after 120 days. Compared to LC/MS/MS, UTRA testing had a 98% positive and 100% negative predictive value.</p><p><strong>Conclusions: </strong>In a sample of YMSM/TGW on daily PrEP, POC UTRA testing predicted PrEP discontinuation more accurately than self-reported adherence, with high predictive values compared to LC/MS/MS. UTRA testing may be a clinical tool for directing preventive interventions towards those likelier to discontinue PrEP despite ongoing HIV vulnerability.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":"1671-1676"},"PeriodicalIF":3.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11293961/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141436525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The construction of a novel supplementary diagnostic model for patients with indeterminate HIV infection.","authors":"Yajun Yan, Rui Yuan, Liping Deng, Hui Hu, Yong Yang, Xien Gui, Rongrong Yang","doi":"10.1097/QAD.0000000000003977","DOIUrl":"10.1097/QAD.0000000000003977","url":null,"abstract":"<p><strong>Introduction: </strong>The window period, defined as HIV nucleic acid test (NAT) reactivity but Western blot (WB) test inconclusive, is garnering more attention. Improving the detection efficiency of HIV high-risk populations in the window period is critical to reducing the risk of unanticipated transmission. The purpose of this study was to create an additional strategy for distinguishing indeterminate HIV infection cases.</p><p><strong>Methods: </strong>Based on WB follow-up results, the individuals in this study were divided into persons in the HIV window period and persons without HIV. Plasma was analyzed using quantitative liquid chromatography-tandem mass spectrometry (LC-MS/MS) to detect differentially expressed proteins (DEPs). The biological implications of these DEPs were investigated using enrichment analysis. Protein-protein interaction (PPI) analysis and LASSO regression were used to identify key proteins. The calibration curve, decision curve, and nomogram were utilized to create the model.</p><p><strong>Results: </strong>Fifty-seven DEPs were screened out, with 33 up-regulated and 24 down-regulated in persons with HIV at window period. The most important Gene Ontology (GO) enrichment items are oxidoreductase activity and heme binding. Oxidoreductases account for half of the 10 main proteins identified from various DEPs. An auxiliary diagnostic model comprised of peroxiredoxin-2 (P32119), band 3 anion transport protein (P02730), and histone H2A type 1 (P0C0S8) was developed. The results of the confusion matrix parameters revealed that this diagnostic approach had strong practicability in distinguishing indeterminate HIV infection cases.</p><p><strong>Conclusions: </strong>The three DEPs identified and predicted by proteomics are useful for the supplemental identification of persons in the HIV window period.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":"1658-1670"},"PeriodicalIF":3.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141615732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Awareness, treatment, and control of hypertension among women at risk or living with HIV in the US South.","authors":"Jessica Blair, Mirjam-Colette Kempf, Jodie A Dionne, Zenoria Causey-Pruitt, Jenni M Wise, Elizabeth A Jackson, Paul Muntner, David B Hanna, Jorge R Kizer, Margaret A Fischl, Igho Ofotokun, Catalina Ramirez, Stephen J Gange, Ilene K Brill, Emily B Levitan","doi":"10.1097/QAD.0000000000003960","DOIUrl":"10.1097/QAD.0000000000003960","url":null,"abstract":"<p><strong>Objectives: </strong>Timely control of hypertension is vital to prevent comorbidities. We evaluated the association of race/ethnicity and HIV infection with incident hypertension outcomes, including awareness, treatment, and control.</p><p><strong>Design: </strong>We evaluated cisgender women living with HIV and sociodemographically matched women living without HIV recruited into four Southern sites of the Women's Interagency HIV Study (WIHS) (2013-2019).</p><p><strong>Methods: </strong>We calculated measurements of the time to four events or censoring: incident hypertension, hypertension awareness, hypertension treatment, and hypertension control. Hazard ratios for race/ethnicity and HIV status were calculated for each outcome using Cox proportional-hazards models adjusted for sociodemographic, behavioral, and clinical risk factors.</p><p><strong>Results: </strong>Among 712 women, 56% were hypertensive at baseline. Forty-five percentage of the remaining women who were normotensive at baseline developed incident hypertension during follow-up. Non-Hispanic white and Hispanic women had faster time to hypertension control compared with non-Hispanic black women ( P  = 0.01). In fully adjusted models, women living with HIV who were normotensive at baseline had faster time to treatment compared with normotensive women living without HIV ( P  = 0.04).</p><p><strong>Conclusion: </strong>In our study of women in the US South, non-Hispanic black women became aware of their hypertension diagnosis more quickly than non-Hispanic white and Hispanic women but were slower to control their hypertension. Additionally, women living with HIV more quickly treated and controlled their hypertension compared with women living without HIV.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":"1703-1713"},"PeriodicalIF":3.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11293969/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141436521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A predictive model for HIV-related lymphoma.","authors":"Shuhei Kurosawa, Yukihiro Yoshimura, Yusuke Takada, Takako Yokota, Masaki Hibi, Ayumi Hirahara, Tsutomu Yoshida, So Okubo, Moe Masuda, Yuna So, Nobuyuki Miyata, Hitomi Nakayama, Aki Sakurai, Kosuke Sato, Chisako Ito, Yoshinobu Aisa, Tomonori Nakazato","doi":"10.1097/QAD.0000000000003949","DOIUrl":"10.1097/QAD.0000000000003949","url":null,"abstract":"<p><strong>Objectives: </strong>To address the paucity of HIV-related lymphoma (HRL)-specific prognostic scores for the Japanese population by analyzing domestic cases of HRL and constructing a predictive model.</p><p><strong>Design: </strong>A single-center retrospective study coupled with a review of case reports of HRL.</p><p><strong>Methods: </strong>We reviewed all patients with HRL treated at our hospital between 2007 and 2023 and conducted a comprehensive search for case reports of HRL from Japan using public databases. A multivariate analysis for overall survival (OS) was performed using clinical parameters, leading to the formulation of the HIV-Japanese Prognostic Index (HIV-JPI).</p><p><strong>Results: </strong>A total of 19 patients with HRL were identified in our institution, whereas the literature review yielded 44 cases. In the HIV-JPI, a weighted score of 1 was assigned to the following factors: age at least 45 years, HIV-RNA at least 8.0×10 4  copies/ml, Epstein-Barr virus-encoded small RNA positivity, and Ann Arbor classification stage IV. The overall score ranged from 0 to 4. We defined the low-risk group as scores ranging from 0 to 2 and the high-risk group as scores ranging from 3 to 4. The 3-year OS probability of the high-risk group [30.8%; 95% confidence interval (CI): 9.5-55.4%) was significantly poorer than that of the low-risk group (76.8%; 95% CI: 52.8-89.7%; P  < 0.01).</p><p><strong>Conclusion: </strong>This retrospective analysis established pivotal prognostic factors for HRL in Japanese patients. The HIV-JPI, derived exclusively from Japanese patients, highlights the potential for stratified treatments and emphasizes the need for broader studies to further refine this clinical prediction model.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":"1627-1637"},"PeriodicalIF":3.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11296280/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141236737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of financial incentives on mental health among adults in HIV care in Lake Zone, Tanzania.","authors":"Pooja Chitle, Lila A Sheira, Emmanuel Katabaro, Solis Winters, Prosper F Njau, Amon Sabasaba, Sandra I McCoy","doi":"10.1097/QAD.0000000000003948","DOIUrl":"10.1097/QAD.0000000000003948","url":null,"abstract":"<p><strong>Objective: </strong>Depression and anxiety are prevalent among people with HIV (PWH), hindering retention in care. Though economic interventions can improve care engagement and mental health in the general population, this remains understudied among PWH. This study assessed whether financial incentives improve mental health among adult antiretroviral therapy (ART) initiates in Lake Zone, Tanzania.</p><p><strong>Design: </strong>Two-arm randomized controlled trial.</p><p><strong>Methods: </strong>From 2021 to 2023, 32 clinics were randomized to offer patients monthly financial incentives (22 500 TSH/US$ 10) for ≤six months (conditional on visit attendance) or standard-of-care (SoC) services. We assessed changes in depression (PHQ-2 scores) and anxiety (GAD-2 scores) symptoms at baseline, six, and 12 months. Difference-in-differences effects were used to estimate changes over time by arm using inverse probability of censoring sample weights (IPCW).</p><p><strong>Results: </strong>Participants ( n  = 1990) were 57.3% female; median age was 35.0. Baseline prevalences of depression and anxiety symptoms were 66.2% and 60.4%, respectively, and endline prevalences were 7.8% and 7.6% in the intervention and SoC arms, respectively, with no differences by arm. Using IPCW, the differences in the prevalence of depression and anxiety symptoms in the intervention arm compared to the SoC arm were 2.5 percentage points [95% confidence interval (CI): -3.0, 8.0) and 2.3 percentage points (95% CI: -3.2, 7.9) respectively after six months, and 5.5 percentage points (95% CI: -0.20, 10.8) and 3.8 percentage points (95% CI: -1.5, 9.2) respectively after 12 months.</p><p><strong>Conclusion: </strong>Both study arms experienced substantial reductions in poor mental health, primarily within the first six months of care. Financial incentives provided in this study did not significantly augment these downward trends but may improve engagement in care, indirectly improving mental health.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":"1677-1685"},"PeriodicalIF":3.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11293976/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141178684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Concomitant use of anabolic androgen steroids and cabotegravir/rilpivirine leading to virological failure and development of two-class resistance.","authors":"David Burger, Eva Wttewaal, Piter Oosterhof, Janneke Stalenhoef","doi":"10.1097/QAD.0000000000003959","DOIUrl":"10.1097/QAD.0000000000003959","url":null,"abstract":"","PeriodicalId":7502,"journal":{"name":"AIDS","volume":"38 11","pages":"1728-1729"},"PeriodicalIF":3.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11296267/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141873905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rosuvastatin was not beneficial in reducing arterial stiffness and may be associated with cardiometabolic adverse events in men with HIV.","authors":"Lweendo Muchaili, Sepiso K Masenga","doi":"10.1097/QAD.0000000000003957","DOIUrl":"https://doi.org/10.1097/QAD.0000000000003957","url":null,"abstract":"","PeriodicalId":7502,"journal":{"name":"AIDS","volume":"38 11","pages":"1720-1721"},"PeriodicalIF":3.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141873908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First-trimester exposure to newer antiretroviral agents and congenital anomalies in a US cohort.","authors":"Kelly Fung, Sonia Hernandez-Diaz, Rebecca Zash, Ellen G Chadwick, Russell B Van Dyke, Carly Broadwell, Jennifer Jao, Kathleen Powis, Lynn M Yee, Paige L Williams","doi":"10.1097/QAD.0000000000003955","DOIUrl":"10.1097/QAD.0000000000003955","url":null,"abstract":"<p><strong>Objective: </strong>To characterize associations of exposure to newer antiretroviral medications in the first trimester with congenital anomalies among infants born to persons with HIV in the United States.</p><p><strong>Design: </strong>Longitudinal cohort of infants born 2012-2022 to pregnant persons with HIV enrolled in the Surveillance Monitoring for ART Toxicities (SMARTT) study.</p><p><strong>Methods: </strong>First-trimester exposures to newer antiretrovirals (ARVs) were abstracted from maternal medical records. Trained site staff conducted physical exams and abstracted congenital anomalies from infant medical records. Investigators classified anomalies using the Metropolitan Atlanta Congenital Defects Program classification system. The prevalence of major congenital anomalies identified by age one year was estimated for infants exposed and unexposed to each ARV. Generalized estimating equation models were used to estimate the odds ratio (OR) of major congenital anomalies for each ARV exposure, adjusting for potential confounders.</p><p><strong>Results: </strong>Of 2034 infants, major congenital anomalies were identified in 135 [6.6%; 95% confidence interval (CI): 5.6-7.8%]. Cardiovascular ( n  = 43) and musculoskeletal ( n  = 37) anomalies were the most common. Adjusted ORs (95% CI) of congenital anomalies were 1.03 (0.62-1.72) for darunavir, 0.91 (0.46-1.81) for raltegravir, 1.04 (0.58-1.85) for rilpivirine, 1.31 (0.71-2.41) for elvitegravir, 0.76 (0.37-1.57) for dolutegravir, and 0.34 (0.05-2.51) for bictegravir, compared to those unexposed to each specific ARV. Findings were similar after adjustment for nucleoside/nucleotide backbones.</p><p><strong>Conclusions: </strong>The odds of congenital anomalies among infants with first-trimester exposure to newer ARVs did not differ substantially from those unexposed to these specific ARVs, which is reassuring. Continued evaluation of these ARVs with larger studies will be needed to confirm these findings.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":"1686-1695"},"PeriodicalIF":3.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11293967/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141305212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Longitudinal controlled attenuation parameter and liver stiffness in children with and without perinatal HIV infection in South Africa.","authors":"Penelope C Rose, Claire Davies, Mark F Cotton, Kennedy Otwombe, Sara H Browne, Florin Vaida, Steve Innes, Etienne De la Rey Nel","doi":"10.1097/QAD.0000000000003964","DOIUrl":"10.1097/QAD.0000000000003964","url":null,"abstract":"<p><strong>Objectives: </strong>Metabolic dysfunction-associated steatotic liver disease (MASLD) is an emerging cause of liver disease in HIV. Transient elastography (TE) with controlled attenuation parameter (CAP) measures liver stiffness as a marker of liver fibrosis and CAP as a measure of hepatic steatosis. Our aim was to evaluate longitudinal CAP and liver stiffness in children with perinatally acquired HIV (PHIV) on antiretroviral therapy (ART) from early life compared to children without HIV (HU).</p><p><strong>Design: </strong>Prospective cohort study.</p><p><strong>Methods: </strong>PHIV and HU were followed annually for two years. During the study, 60% of PHIV switched from older ART regimens to tenofovir disoproxil, lamivudine and dolutegravir (TLD). Longitudinal evolution of CAP and liver stiffness were investigated in two PHIV groups - on older ART and on TLD - compared to HU children using linear mixed effects models.</p><p><strong>Results: </strong>263 children and adolescents (112 PHIV, 151 HU) aged 7-20 years were followed. PHIV on older ART had CAP 8.61% (95% CI 4.42-12.97, P  < 0.001) greater than HU and no significant difference in CAP between PHIV on TLD and HU. No significant difference in liver stiffness was found between PHIV on older ART regimens and PHIV on TLD compared to HU.</p><p><strong>Conclusion: </strong>PHIV on older ART had higher CAP than HU, whereas in PHIV switched to TLD there was no difference in CAP compared to HU. There was no difference in liver stiffness between either PHIV group and HU. This suggests starting ART early in life might protect PHIV from developing hepatic fibrosis.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":"1638-1647"},"PeriodicalIF":3.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11317452/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141436524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cervical cancer screening integrated in routine clinical care of women with HIV.","authors":"Emma J P N Gram, Ellen Moseholm, Anne B Nørløv, Charlotte Wilken-Jensen, Kristina Thorsteinsson, Birgitte T Pedersen, Sussie M Jørgensen, Jesper Bonde, Lars H Omland, Anne-Mette Lebech, Nina Weis","doi":"10.1097/QAD.0000000000003972","DOIUrl":"10.1097/QAD.0000000000003972","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate if integrated cervical cancer screening (CCS) for women with HIV (WWH) in routine HIV care resulted in increased adherence to screening, and to describe the prevalence of human papillomavirus (HPV)-specific genotypes and the incidence of cellular abnormalities.</p><p><strong>Design: </strong>Cohort study.</p><p><strong>Methods: </strong>WWH who accepted the offer of combined CCS and HIV care (group 1), WWH who declined the offer (group 2), and WWH not offered CCS within HIV care (group 3) between 2013 and 2019 were included. Data was collected from The Danish HIV Cohort Study and The Danish Pathology Data Bank. Adherence to the CCS program was defined as fulfilled if WWH were screened annually.</p><p><strong>Results: </strong>A total of 804 WWH were included. WWH who accepted CCS within HIV care (group 1; n  = 218) had significantly higher adherence to screening in all study years 22-99% compared with the WWH who declined CCS (group 2; n  = 232) 10-16% and WWH who were not invited for CCS (group 3; n  = 354) 11-25%. There was no significant difference in the prevalence of HPV-specific genotypes and incidence of cellular abnormalities among the three groups.</p><p><strong>Conclusion: </strong>Integrating CCS for WWH in routine HIV care resulted in higher adherence to the CCS guidelines. Combined services thereby represent an opportunity to engage WWH in HIV care into preventive services.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":"1648-1657"},"PeriodicalIF":3.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141475726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}